Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.
Tsukahara T, Emori M, Murata K, Hirano T, Muroi N, Kyono M, Toji S, Watanabe K, Torigoe T, Kochin V, Asanuma H, Matsumiya H, Yamashita K, Himi T, Ichimiya S, Wada T, Yamashita T, Hasegawa T, Sato N. Tsukahara T, et al. Among authors: watanabe k. J Biol Chem. 2014 Aug 8;289(32):22035-47. doi: 10.1074/jbc.M114.568725. Epub 2014 Jun 24. J Biol Chem. 2014. PMID: 24962571 Free PMC article.
Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R, Hirohashi Y, Asano T, Mariya T, Suzuki T, Takaya A, Saijo H, Shionoya Y, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Watanabe K, Atsuyama E, Toji S, Hirano H, Hasegawa T, Takahashi H, Sato N, Torigoe T. Horibe R, et al. Among authors: watanabe k. PLoS One. 2017 Mar 1;12(3):e0171460. doi: 10.1371/journal.pone.0171460. eCollection 2017. PLoS One. 2017. PMID: 28248963 Free PMC article.
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.
Kochin V, Kanaseki T, Tokita S, Miyamoto S, Shionoya Y, Kikuchi Y, Morooka D, Hirohashi Y, Tsukahara T, Watanabe K, Toji S, Kokai Y, Sato N, Torigoe T. Kochin V, et al. Among authors: watanabe k. Oncoimmunology. 2017 Feb 16;6(4):e1293214. doi: 10.1080/2162402X.2017.1293214. eCollection 2017. Oncoimmunology. 2017. PMID: 28533942 Free PMC article.
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
Kubo T, Tsurita G, Hirohashi Y, Yasui H, Ota Y, Watanabe K, Murai A, Matsuo K, Asanuma H, Shima H, Wada S, Nakatsugawa M, Kanaseki T, Tsukahara T, Mizuguchi T, Hirata K, Takemasa I, Imai K, Sato N, Torigoe T. Kubo T, et al. Among authors: watanabe k. Cancer Sci. 2019 Aug;110(8):2386-2395. doi: 10.1111/cas.14099. Epub 2019 Jul 11. Cancer Sci. 2019. PMID: 31206934 Free PMC article. Clinical Trial.
Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.
Shionoya Y, Kanaseki T, Miyamoto S, Tokita S, Hongo A, Kikuchi Y, Kochin V, Watanabe K, Horibe R, Saijo H, Tsukahara T, Hirohashi Y, Takahashi H, Sato N, Torigoe T. Shionoya Y, et al. Among authors: watanabe k. Oncoimmunology. 2017 Jan 3;6(2):e1274476. doi: 10.1080/2162402X.2016.1274476. eCollection 2017. Oncoimmunology. 2017. PMID: 28344889 Free PMC article.
Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma.
Tsukahara T, Watanabe K, Murata K, Takahashi A, Mizushima E, Shibayama Y, Kameshima H, Hatae R, Ohno Y, Kawahara R, Murai A, Nakatsugawa M, Kubo T, Kanaseki T, Hirohashi Y, Terui T, Asanuma H, Hasegawa T, Sato N, Torigoe T. Tsukahara T, et al. Among authors: watanabe k. Cancer Immunol Immunother. 2020 Feb;69(2):189-197. doi: 10.1007/s00262-019-02455-0. Epub 2019 Dec 18. Cancer Immunol Immunother. 2020. PMID: 31853575 Free PMC article.
16,512 results
You have reached the last available page of results. Please see the User Guide for more information.